Researcher
Patrick Chaltin
- Disciplines:Laboratory medicine, Palliative care and end-of-life care, Regenerative medicine, Other basic sciences, Other health sciences, Nursing, Other paramedical sciences, Other translational sciences, Other medical and health sciences
Affiliations
- Intellectual Property (Administrative office)
Member
From16 Mar 2006 → 10 Apr 2017 - Department of Microbiology, Immunology and Transplantation (Department)
Member
From15 May 2002 → 31 Oct 2002 - Medicinal Chemistry (Rega Institute) (Division)
Member
From1 Oct 1999 → 14 May 2002
Projects
1 - 10 of 16
- ATP13A2 agonists for Parkinson’s disease therapyFrom1 Mar 2024 → TodayFunding: IOF - technology validation in lab
- PHGDH-ASM: Phosphoglycerate dehydrogenase (PHGDH) activators as novel antiseizure medications (ASM) with dual mode of actionFrom1 Oct 2022 → TodayFunding: IOF - technology validation in lab
- VirusBank platform (state-of-the-art research platform for increased preparedness against viral epidemics and pandemics)From1 Jan 2022 → TodayFunding: Ministery of Economical Affairs
- Targeting transcription factor addiction in acute leukemia (TaTFAL)From1 Oct 2021 → TodayFunding: FWO Strategic Basic Research (SBO)
- Understanding the anti-cancer effects of new YAP/TAZ inhibitors to treat malignant mesotheliomaFrom1 Mar 2021 → TodayFunding: Foundations, funds and other with scientific goal
- MATATUM: Validation and druggability development of macrophage-specific targets in the tumor microenvironment.From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Targeting ZEB pathways to tackle aggressive (colorectal) cancer (ZENTACC).From1 Jan 2018 → 31 Dec 2021Funding: FWO Strategic Basic Research (SBO)
- Towards a combined post-exposure prophylaxis and successful treatment of rabies in humansFrom1 Oct 2017 → 30 Sep 2020Funding: FWO research project (including WEAVE projects)
- Valorization of novel strategies for the prevention of viral infection and inhibition of viral replication.From1 Nov 2015 → TodayFunding: IOF - Industrial Research Fund, IOF - mandates
- iKap: Targeting nucleocytoplasmic transport for novel anti-cancer therapy.From1 Oct 2015 → 30 Nov 2019Funding: SBO (Strategic basic research)
Publications
11 - 20 of 44
- Differential antiviral activities of respiratory syncytial virus (RSV) inhibitors in human airway epithelium(2018)
Authors: Carmen Mirabelli, Mieke Boon, Mark Jorissen, Patrick Chaltin, Johan Neyts, Dirk Jochmans
Pages: 1823 - 1829 - Interruption of lactate uptake by inhibiting mitochondrial pyruvate transport unravels direct antitumor and radiosensitizing effects(2018)
Authors: Nihed Draoui, Patrick Chaltin
- Inhibitors of the Integrase–Transportin-SR2 interaction block HIV nuclear import(2018)
Authors: Jonas Demeulemeester, Jolien Blokken, Stéphanie De Houwer, Lieve Dirix, Arnaud Marchand, Patrick Chaltin, Frauke Christ, Zeger Debyser
- An allosteric binding site of the alpha 7 nicotinic acetylcholine receptor revealed in a humanized acetylcholine-binding protein(2018)
Authors: Fabian Gruss, Sam Noppen, Steve Peigneur, Patrick Chaltin, Sandra Liekens, Jan Tytgat, Chris Ulens
Pages: 2534 - 2545 - 1-((2,4-Dichlorophenethyl)Amino)3-Phenoxypropan-2-ol Kills Pseudomonas aeruginosa through Extensive Membrane Damage(2018)
Authors: Valerie Defraine, Veerle Liebens, Toon Swings, Bram Weytjens, Kathleen Marchal, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart, Jan Michiels
- Antibacterial Activity of 1-[(2,4-Dichlorophenethyl)amino]-3-Phenoxypropan-2-ol against Antibiotic-Resistant Strains of Diverse Bacterial Pathogens, Biofilms and in Pre-clinical Infection Models(2017)
Authors: Valerie Defraine, Laure Verstraete, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart, Jan Michiels
Pages: 2585 - Identification of 1-((2,4-Dichlorophenethyl)Amino)-3-Phenoxypropan-2-ol, a Novel Antibacterial Compound Active against Persisters of Pseudomonas aeruginosa(2017)
Authors: Veerle Liebens, Valerie Defraine, Wouter Knapen, Toon Swings, Arnaud Marchand, Patrick Chaltin, Maarten Fauvart, Jan Michiels
- Discovery of a new Mycobacterium tuberculosis thymidylate synthase X inhibitor with a unique inhibition profile(2017)
Authors: Rania Abou El Asrar, Arnaud Marchand, Patrick Chaltin, Steven De Jonghe, Piet Herdewyn, Eveline Lescrinier
Pages: 69 - 78 - Synthetic strategy and antiviral evaluation of diamide containing heterocycles targeting dengue and yellow fever virus(2016)
Authors: Joanna Zmurko, Suzanne Kaptein, Jef Rozenski, Bharat Gadakh, Patrick Chaltin, Arnaud Marchand, Johan Neyts, Arthur Van Aerschot
Pages: 158 - 168 - Elucidation of the mode of action of a new antibacterial compound active against Staphylococcus aureus and Pseudomonas aeruginosa(2016)
Authors: Evelien Gerits, Eline Blommaert, Bram Weytjens, Dries De Maeyer, Kathleen Marchal, Arnaud Marchand, Patrick Chaltin, Pieter Spincemaille, Katrijn De Brucker, Karin Thevissen, et al.
Patents
1 - 10 of 10
- Aryl derivatives for treating trpm3 mediated disorders (Inventor)
- Heterocycle derivatives for treating trpm3 mediated disorders (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders (Inventor)
- Compounds for the treatment of epilepsy, neurodegenerative disorders and other cns disorders (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- Thieno[2,3-b]pyridine derivatives as viral replication inhibitors (Inventor)
- Indole amide derivatives and related compounds for use in the treatment of neurodegenerative diseases (Inventor)
- N-((1h-indol-3-yl)-alkyl)-4-benzyl)benzamide and n-((1h-pyrrolo[2,3-b]pyridin-3-yl)-alkyl)-4-benzyl)benzamide derivatives as alpha synuclein aggregation inhibitors for the treatment of neurodegenerative disorders (Inventor)
- Compounds for the treatment of neurodegenerative diseases (Inventor)